Agenus shared a post on LinkedIn:
“Stay tuned for AACR25, where Dr. Anthony El-khoueiry will present data from our Phase 1 trial evaluating botensilimab/balstilimab in treatment-refractory hepatocellular carcinoma (HCC).
More posts featuring Agenus.
Photo: investor.agenusbio.com